peppersite
Peptidesubcutaneous

DSIP

DSIP, or delta sleep-inducing peptide, is a small natural peptide of nine amino acids, first isolated in the 1970s from the blood of sleeping rabbits. It has been studied mostly in animals and in a handful of small human sleep trials.

Researched for
Sleep

At a glance

Type
Peptide
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
100 mcg per Peptide Dosing Protocols. All 2 sources
Typical vial
10 mg in 2 mL

How much to draw

Full calculator →
Your draw
2units
0.02 mL on a U-100 insulin syringe
5 mg/mL100 doses per vial
Amount per dose

Opened on 100 mcg, the figure Peptide Dosing Protocols reports for DSIP, and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for DSIP or for anything else, and nothing below has been checked against the study it came from.

100-300 mcg subcutaneous; 25 nmol/kg IV (~1.5 mg for 70 kg person)
Frequency
Once daily before bed; or every 2-3 dayshave not been established.
Route
subcutaneous or intranasal
Reported by
Peptide Protocol Wiki
Standard: 100-200 mcg · Low: 100 mcg · High: 300 mcg
Frequency
once daily5-7 nights · short course
Route
SubQ
Reported by
Peptide Dosing Protocols
What it saysThe standard dosing for DSIP is 100-200 mcg subcutaneously once daily.
Reconstitution, as reported
  • Bacteriostatic water
  • 2.0 mL bacteriostatic water
Not yet audited

We have not published an audit on DSIP. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

DSIP appears to shift the pattern of sleep, particularly deep slow-wave sleep, rather than acting as a sedative. Reviews link it to NMDA receptors, alpha-adrenergic signalling, opioid receptors and the hypothalamic-pituitary-adrenal axis, the system that runs stress hormones, and DSIP-like material has been found in the hypothalamus, limbic system, pituitary and gut. The precise receptor and mechanism are still not established, and the small human trials from 1981-1987, with 6-14 subjects each, disagreed on whether any improvement beat placebo.

In technical termsSleep-related neuropeptide signaling.

Reported side effects

Seen in studies: early human trials and reviews described DSIP as well tolerated at the doses tested, with mild, passing headache, nausea or dizziness in some subjects.

Not ruled out: long-term safety has not been established. Research write-ups mention possible morning sluggishness or vivid dreams, the FDA flagged theoretical immune reactions when it placed the peptide on its Category 2 list, and any interaction with stress-hormone signalling has not been characterised in modern trials. Purity, contamination and mislabelling are separate risks for any research-use peptide.

Who should avoid it

People who are pregnant or breastfeeding: DSIP has not been studied in pregnancy or lactation.

Children and adolescents: there is no human data in this age group.

People with untreated obstructive sleep apnoea: any sleep-modulating compound is described as warranting clinical oversight.

People with active substance dependence: the published withdrawal trials were small and ran in clinical settings rather than self-directed ones.

People with adrenal or thyroid disease: DSIP can interact with stress-hormone signalling, so clinical oversight is warranted.

People taking sedating medicines: the combined effects are not well characterised.

What gets monitored

CBC with differential and comprehensive metabolic panel (CMP) at baseline; optional TSH and free T4, and A1c as needed. (reported by Peptide Dosing Protocols)

Common questions

What is DSIP peptide?

DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide. It was first isolated in 1974 from the blood of sleeping rabbits.

Is DSIP FDA-approved?

No. DSIP is not FDA-approved for any human indication. The FDA refers to it as Emideltide and placed it on the Category 2 list in September 2023, with a compounding advisory committee review scheduled for July 2026.

What doses of DSIP appear in the research?

Reported amounts and schedules for DSIP differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

How is DSIP reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

When is DSIP usually injected in reported protocols?

Most research write-ups describe a single evening subcutaneous dose, 1-3 hours before intended sleep. That timing comes from write-ups rather than from a controlled trial.

What are the reported side effects of DSIP?

Mild, passing headache, nausea and occasional dizziness have been reported in early human studies. Long-term safety has not been established.

How does DSIP compare to melatonin?

DSIP is described as modulating the architecture of sleep, while melatonin mainly shifts the timing of sleep. Neither comparison rests on a modern head-to-head trial in the source material.

Is this page medical advice?

No. It is an educational research reference. DSIP has no FDA-approved indication, dose or population.

Sources

  1. 01Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and Biobehavioral Reviews (1984)
  2. 02Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides (1986)
  3. 03Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry (2006)
  4. 04Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia (1981)
  5. 05Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology (1987)
  6. 06Salgado-Puga K, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. European Neurology (1987)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
CJC-1295

CJC-1295 No DAC, also called Modified GRF 1-29, is a short-acting lab-made copy of growth-hormone-releasing hormone (GHRH), the body's signal to release growth hormone. Published human studies cover the parent CJC-1295 compound, and no large trial has tested the No DAC version.

CJC-1295 / Ipamorelin (GH Pulse)

GH Pulse is a combination sold as one vial: CJC-1295, a copy of growth hormone-releasing hormone, together with Ipamorelin, a selective growth hormone secretagogue. It is studied for growth-hormone-axis support, recovery and body composition.

Epitalon

Epitalon, also spelled epithalon, is a lab-made peptide of four amino acids (Ala-Glu-Asp-Gly), also called AEDG. It is studied mainly for aging, in cells, in animals and in older non-blinded human work on the related pineal extract.

Ipamorelin

Ipamorelin, also called NNC 26-0161, is a lab-made peptide that prompts the pituitary gland to release a short pulse of the body's own growth hormone. It has been tested in healthy volunteers and in a trial of slow gut recovery after bowel surgery, where it did not show benefit.

Selank

Selank is a lab-made peptide of seven amino acids, based on tuftsin, a small immune-related molecule the body makes on its own. It has been studied mainly in Russian human trials of anxiety, and in animal work on nerve-cell growth signals.

Sermorelin Acetate

Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.